Erasca
Erasca Inc is an American clinical-stage precision oncology biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for patients with RAS/MAPK pathway-driven cancers. The company utilizes its proprietary drug discovery platforms to develop novel therapeutic candidates designed to shut down cancer cell proliferation and overcome drug resistance in solid tumors and hematologic malignancies. Its core business activities encompass preclinical oncology research, clinical trial management, genetic biomarker analysis, and pharmaceutical drug design. As a clinical-stage biotechnology firm, the company generates minimal commercial revenue and finances its drug pipeline through public equity offerings and pharmaceutical research collaborations. Erasca holds a pioneering position in targeted RAS/MAPK pathway oncology therapeutics. The company is headquartered in San Diego, California, United States, and its common stock trades on the Nasdaq Global Select Market.
6 of the funds FundTelligence covers report a position in Erasca.
- Legal name
- Erasca Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 6
- Exposure themes
- Precision Medicine & Genomics, Precision Oncology, Precision Therapeutics
Funds holding Erasca
- Schroder ISF Healthcare Innovation — Schroders · 0.67 % (full portfolio disclosed, June 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.42 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.32 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.03 % (partially disclosed portfolio, June 2026)